Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | METAP2 | P50579 | 6/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | USP8 | P40818 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 4/20 | 0.41 |
| ▸ | FABP4 | P15090 | 2/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25072774 | 0.88 | METAP2 (0.40) | KDM4EMETAP2USP2USP8ACLY | |
| SCHEMBL25072800 | 0.86 | METAP2 (0.39) | KDM4EMETAP2USP2USP8ACLY | |
| SCHEMBL25734379 | 0.82 | KDM4E (0.51) | KDM4EUSP2USP8ACLYFABP4 | |
| SCHEMBL25073333 | 0.81 | KDM4E (0.47) | KDM4EUSP2USP8ACLYFABP4 | |
| SCHEMBL25072519 | 0.81 | KEAP1 (0.44) | METAP2USP2USP8ACLYFABP4 | |
| SCHEMBL25073206 | 0.81 | KDM4E (0.49) | KDM4EUSP2USP8ACLY | |
| SCHEMBL25072997 | 0.80 | KDM4E (0.43) | KDM4EMETAP2USP2USP8ACLY | |
| SCHEMBL25072812 | 0.80 | KDM4E (0.39) | KDM4EMETAP2USP2USP8ACLY | |
| SCHEMBL25073104 | 0.80 | KDM4E (0.46) | KDM4EACLYFABP4CSNK2A2CSNK2A1 | |
| SCHEMBL25073171 | 0.80 | ALDH1A1 (0.44) | KDM4EACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023023310-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | HSD17B1, HSD17B13, HSD17B3 | KDM4E 2637/4885METAP2 2043/4885USP2 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.